ProofPilot + Lokavant for Improved Trial Conduct: Interview Highlights with Clinical Trial Vanguard

ProofPilot’s acquisition of Lokavant is a move that will have a significant, high-value impact on clinical trial performance and outcomes.  

Chris Venezia, ProofPilot CEO, and Joseph Kim, Chief Strategy Officer, sat down recently with Clinical Trial Vanguard for a close look at the industry challenges the integration of the two platforms will address, and how it will translate into real value for sponsors.  

From reliable, real-time decision-making to proactive interventions, let’s look at what we’ve unleashed by combining these two powerful solutions.   

First things first

ProofPilot’s bread and butter is enabling flawless day-to-day trial execution. Lokavant, on the other hand, excels in reporting, analytics, and prediction. This means the integration hinges less on feature overlap and more on its complementary use cases.  

The combination of the two platforms aims to provide a seamless end-to-end experience with a single dashboard that ties operational actions to predictive insights, with outcomes based in clinical data. The result? A practical framework for higher quality trials, faster decisions, and measurable outcomes. 

Not just another dashboard

Let’s be clear: we're not just throwing another dashboard into the mix. The product is a reliable action framework that combines leading indicators with lagging indicators, to turn forecasts into concrete actions for tangible results.  

Here’s how it works: 

1. Identify a predictive signal 
2. Implement targeted training or procedural adjustments 
3. Observe measurable improvement in trial performance across multiple studies 

This empowers teams to adopt new practices, monitor results, and adjust in real-time. 

Cause and effect

“Imagine a site deviation where the platform can trace it back to a clear cause,” Chris said. “Certain content that was not accessed, what guidance was consulted, and how interpretations may have diverged.”  

Simply put: we want to make it easier to identify the cause and effect of site performance. In order for corrective actions to be iterative and scalable, Sponsors need the ability to connect day-to-day engagement and behavior with outcomes.  

With end-to-end visibility, Sponsors are better equipped to understand actions and impact.  

Proactive, not reactive

“Real-time traceability means you don’t wait for an audit to know what happened,” Joe said in the interview. 

Measurable improvements in study conduct can be achieved when behavior signals are used to trigger prompt intervention before it’s too late. Ultimately, this practice results in fewer repeat mistakes and faster optimization.  

Think proactive prevention rather than reactive fixes—and not only for the current study, but future studies as well.  

Ready for a closer look?

Read Chris and Joe’s full interview with Clinical Trial Vanguard for a deeper exploration of the ProofPilot-Lokavant combined capabilities. 

For extra credit, book a call with us to discuss how our end-to-end platform can transform your study conduct.